White Paper for Download
Leveraging SaaS Platforms to Align with EMA Guidelines for ATMP Clinical Trials
Preparing for EMA 2025 Advanced Therapy Medicinal Product (ATMP) guidelines? Discover how (Software-as-a-Service) SaaS platforms for cell laboratory management support compliance through digital batch records, bi-directional lineage tracking, and end-to-end traceability in ATMP manufacturing.
.jpeg)
What We
Cover
Learn how to prepare your ATMP workflows for updated EMA guidelines with digital systems that support:
- EMA regulatory expectations for data integrity, Good Manufacturing Practice (GMP) documentation, and audit readiness
- SaaS infrastructure tailored to personalized cell and gene therapy process development
- Real-time traceability of reagents, raw materials, and equipment usage
- Bi-directional lineage tracking across cells, ingredients, and manufacturing inputs
- Standardized digital protocols and master batch records aligned with global compliance standards
Is Your ATMP Operation Ready for EMA 2025 Guidelines?
In this guide, you’ll learn how digital transformation and LIMS can help you solve:
Understand how updated EMA standards require complete visibility of processes, materials, and data—and why digital readiness is critical for ATMP regulatory success.
See how SaaS systems designed for cell and gene therapy unify culture, banking, and biomanufacturing workflows to reduce risk and improve operational control.
Learn how validated digital systems support electronic signatures, secure records, and audit trails to satisfy EMA guidelines and broader global compliance frameworks.
Learn how validated digital systems support electronic signatures, secure records, and audit trails to satisfy EMA guidelines and broader global compliance frameworks.
Take the Next Step Toward Digital ATMP Compliance
